Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.
(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).
Navigating the Complexities of Smell Loss in Patients with CRSwNP.
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?
This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.
Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium
Understanding type 2 inflammation* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.1
Du er i ferd med å forlate campus.sanofi/no. Sanofi er ikke ansvarlig for innholdet på dette eksterne Nettstedet.
Denne nettsiden inneholder informasjon som er kun for helsepersonell som lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, samt studenter i disse fag.
